Sarcoma and germ-line DICER1 mutations - Authors' reply

Affiliations

¹ Garvan Institute of Medical Research, The Kinghorn Cancer Centre and Cancer Division, Darlinghurst, NSW 2010, Australia.
² Garvan Institute of Medical Research, The Kinghorn Cancer Centre and Cancer Division, Darlinghurst, NSW 2010, Australia. Electronic address: d.thomas@garvan.org.au.

Comment

Mandy L Ballinger et al. Lancet Oncol. 2016 Nov.

. 2016 Nov;17(11):e471.

doi: 10.1016/S1470-2045(16)30527-7.

¹ Garvan Institute of Medical Research, The Kinghorn Cancer Centre and Cancer Division, Darlinghurst, NSW 2010, Australia.
² Garvan Institute of Medical Research, The Kinghorn Cancer Centre and Cancer Division, Darlinghurst, NSW 2010, Australia. Electronic address: d.thomas@garvan.org.au.

No abstract available

Comment on

Monogenic and polygenic determinants of sarcoma risk: an international genetic study.
Ballinger ML, Goode DL, Ray-Coquard I, James PA, Mitchell G, Niedermayr E, Puri A, Schiffman JD, Dite GS, Cipponi A, Maki RG, Brohl AS, Myklebost O, Stratford EW, Lorenz S, Ahn SM, Ahn JH, Kim JE, Shanley S, Beshay V, Randall RL, Judson I, Seddon B, Campbell IG, Young MA, Sarin R, Blay JY, O'Donoghue SI, Thomas DM; International Sarcoma Kindred Study. Ballinger ML, et al. Lancet Oncol. 2016 Sep;17(9):1261-71. doi: 10.1016/S1470-2045(16)30147-4. Epub 2016 Aug 4. Lancet Oncol. 2016. PMID: 27498913
Sarcoma and germ-line DICER1 mutations.
de Kock L, Foulkes WD. de Kock L, et al. Lancet Oncol. 2016 Nov;17(11):e470. doi: 10.1016/S1470-2045(16)30522-8. Lancet Oncol. 2016. PMID: 27819237 No abstract available.